Perek Nathalie, Le Jeune Nathalie, Denoyer Delphine, Dubois Francis
Laboratory of Biophysics, Research Group EA 3063 Cellular Survival and Adhesion in Tumors and Grafts-Faculty of Medicine, Saint-Etienne, France.
Cancer Biother Radiopharm. 2005 Aug;20(4):391-400. doi: 10.1089/cbr.2005.20.391.
The main cause of the multidrug resistance (MDR) of glioma cells is the overexpression of MRP-1, often associated with high levels of glutathione (GSH). We investigated whether MRP-1-related GSH content can influence (99m)Tc-glucarate entry by comparing its uptake with that of (99m)Tc-sestamibi (MIBI), an MRP- 1 probe, in an in vitro model of a sensitive cell line (U-87-MG) and a resistant derived cell line expressing MRP-1 (U-87-MG-R). Drug resistance was assessed by immunoblotting, GSH measurement, and Alamar Blue assay. To correlate MDR phenotype with tracer accumulation, uptakes were performed with and without modulators and after GSH depletion. Similar accumulation of (99m)Tc-glucarate was observed in the two cell lines, and the use of MDR reversals did not enhance its uptake. Our results clearly demonstrate that (99m)Tc-glucarate uptake is not related to MRP-1 expression or GSH levels. In contrast, (99m)Tc- MIBI accumulation is inversely proportional to the cell MDR phenotype. The combination of (99m)Tc-glucarate and (99m)Tc-MIBI may be a useful tool for the noninvasive detection of malignant sites and their chemoresistance status.
胶质瘤细胞多药耐药(MDR)的主要原因是多药耐药相关蛋白1(MRP-1)的过度表达,这通常与高水平的谷胱甘肽(GSH)有关。我们通过在敏感细胞系(U-87-MG)和表达MRP-1的耐药衍生细胞系(U-87-MG-R)的体外模型中比较(99m)锝葡糖醛酸的摄取与MRP-1探针(99m)锝甲氧基异丁基异腈(MIBI)的摄取,研究了与MRP-1相关的GSH含量是否会影响(99m)锝葡糖醛酸的摄取。通过免疫印迹、GSH测量和阿拉玛蓝测定法评估耐药性。为了将MDR表型与示踪剂积累相关联,在有和没有调节剂的情况下以及在GSH耗竭后进行摄取。在两种细胞系中观察到(99m)锝葡糖醛酸的相似积累,并且使用MDR逆转剂并未增强其摄取。我们的结果清楚地表明,(99m)锝葡糖醛酸的摄取与MRP-1表达或GSH水平无关。相比之下,(99m)锝MIBI的积累与细胞MDR表型成反比。(99m)锝葡糖醛酸和(99m)锝MIBI的联合使用可能是一种用于恶性部位及其化疗耐药状态无创检测的有用工具。